498 related articles for article (PubMed ID: 25739719)
41. The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients-the Polish Lymphoma Research Group (PLRG) Observational Study.
Zaucha JM; Malkowski B; Chauvie S; Subocz E; Tajer J; Kulikowski W; Fijolek-Warszewska A; Biggi A; Fallanca F; Kobylecka M; Dziuk M; Woszczyk D; Rybka J; Kroll-Balcerzak R; Bergesio F; Romanowicz A; Chamier-Cieminska A; Kurczab P; Giza A; Lesniewski-Kmak K; Zaucha R; Swietlik D; Wróbel T; Knopinska-Posluszny W; Walewski J; Gallamini A
Ann Oncol; 2017 Dec; 28(12):3051-3057. PubMed ID: 28950332
[TBL] [Abstract][Full Text] [Related]
42. Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD × two cycles followed by FDG-PET/CT restaging and 20 Gy of involved-site radiotherapy.
Kamran SC; Jacene HA; Chen YH; Mauch PM; Ng AK
Leuk Lymphoma; 2018 Jun; 59(6):1384-1390. PubMed ID: 28937297
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment.
Cencini E; Fabbri A; Rigacci L; Lazzi S; Gini G; Cox MC; Mancuso S; Abruzzese E; Kovalchuk S; Goteri G; Di Napoli A; Bono R; Fratoni S; Di Lollo S; Bosi A; Leoncini L; Bocchia M
Hematol Oncol; 2017 Mar; 35(1):69-78. PubMed ID: 26251194
[TBL] [Abstract][Full Text] [Related]
44. Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma.
Song MK; Chung JS; Lee JJ; Jeong SY; Lee SM; Hong JS; Chong A; Moon JH; Kim JH; Lee SM; Kim SJ; Shin HJ
Cancer Sci; 2013 Dec; 104(12):1656-61. PubMed ID: 24033666
[TBL] [Abstract][Full Text] [Related]
45. Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation.
Mesguich C; Cazeau AL; Bouabdallah K; Soubeyran P; Guyot M; Milpied N; Bordenave L; Hindié E
Br J Haematol; 2016 Nov; 175(4):652-660. PubMed ID: 27539369
[TBL] [Abstract][Full Text] [Related]
46. Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease.
Guadagnolo BA; Punglia RS; Kuntz KM; Mauch PM; Ng AK
J Clin Oncol; 2006 Sep; 24(25):4116-22. PubMed ID: 16943528
[TBL] [Abstract][Full Text] [Related]
47. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?
Laskar S; Gupta T; Vimal S; Muckaden MA; Saikia TK; Pai SK; Naresh KN; Dinshaw KA
J Clin Oncol; 2004 Jan; 22(1):62-8. PubMed ID: 14657226
[TBL] [Abstract][Full Text] [Related]
48. [Resistance to first line chemotherapy treatment in a patient diagnosed of nodular lymphocyte-predominant Hodgkin's lymphoma identified by 18F-FDG PET/CT: diagnostic and therapeutic implications].
Banzo J; Ubieto MA; Giraldo P; Razola P; Prats E; Tardin L; Santapau A; Parra A; Rambalde EF; Velilla J
Rev Esp Med Nucl Imagen Mol; 2012; 31(2):89-92. PubMed ID: 21620527
[TBL] [Abstract][Full Text] [Related]
49. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
50. Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study.
Barrington SF; Phillips EH; Counsell N; Hancock B; Pettengell R; Johnson P; Townsend W; Culligan D; Popova B; Clifton-Hadley L; McMillan A; Hoskin P; O'Doherty MJ; Illidge T; Radford J
J Clin Oncol; 2019 Jul; 37(20):1732-1741. PubMed ID: 31112475
[TBL] [Abstract][Full Text] [Related]
51. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
[TBL] [Abstract][Full Text] [Related]
52. Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study Group.
Kriz J; Reinartz G; Dietlein M; Kobe C; Kuhnert G; Haverkamp H; Haverkamp U; Engenhart-Cabillic R; Herfarth K; Lukas P; Schmidberger H; Staar S; Hegerfeld K; Baues C; Engert A; Eich HT
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):46-53. PubMed ID: 25863753
[TBL] [Abstract][Full Text] [Related]
53. Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study.
Pavlovsky S; Corrado C; Pavlovsky MA; Prates MV; Zoppegno L; Giunta M; Cerutti I; Palomino E; Pagani F; Lastiri F; Bar D; Bezares RF; Avila G
Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):181-5. PubMed ID: 20511162
[TBL] [Abstract][Full Text] [Related]
54. Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography-Directed Therapy for Early-Stage Hodgkin Lymphoma.
Cutter DJ; Ramroth J; Diez P; Buckle A; Ntentas G; Popova B; Clifton-Hadley L; Hoskin PJ; Darby SC; Radford J; Illidge T
J Clin Oncol; 2021 Nov; 39(32):3591-3601. PubMed ID: 34388007
[TBL] [Abstract][Full Text] [Related]
55. Involved-site image-guided intensity modulated versus 3D conformal radiation therapy in early stage supradiaphragmatic Hodgkin lymphoma.
Filippi AR; Ciammella P; Piva C; Ragona R; Botto B; Gavarotti P; Merli F; Vitolo U; Iotti C; Ricardi U
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):370-5. PubMed ID: 24613810
[TBL] [Abstract][Full Text] [Related]
56. Ability of final PET/CT to predict response to first-line treatment in real patients with classical Hodgkin lymphoma.
Galvez-Carvajal L; Quero C; Casanova M; Díaz C; Chícharo JR; Espeso M; Medina Á; Ramos I; Alba E; Rueda A
Int J Hematol; 2022 Jan; 115(1):54-60. PubMed ID: 34546542
[TBL] [Abstract][Full Text] [Related]
57. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
Castillo JJ; Bower M; Brühlmann J; Novak U; Furrer H; Tanaka PY; Besson C; Montoto S; Cwynarski K; Abramson JS; Dalia S; Bibas M; Connors JM; Furman M; Nguyen ML; Cooley TP; Beltran BE; Collins JA; Vose JM; Xicoy B; Ribera JM;
Cancer; 2015 Feb; 121(3):423-31. PubMed ID: 25251326
[TBL] [Abstract][Full Text] [Related]
58. Combination chemoradiotherapy in early Hodgkin lymphoma.
André MP
Hematol Oncol Clin North Am; 2014 Feb; 28(1):33-47. PubMed ID: 24287066
[TBL] [Abstract][Full Text] [Related]
59. Prospective study of combined modality treatment or radiotherapy alone in the management of early-stage adult Hodgkin's disease.
Yildiz F; Zengin N; Engin H; Güllü I; Barista I; Caglar M; Ozyar E; Cengiz M; Gürkaynak M; Zorlu F; Caner B; Atahan IL; Tekuzman G
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):839-46. PubMed ID: 15465201
[TBL] [Abstract][Full Text] [Related]
60. Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.
Zinzani PL; Derenzini E; Pellegrini C; Celli M; Broccoli A; Argnani L
Br J Haematol; 2013 Dec; 163(5):681-3. PubMed ID: 24032977
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
